An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 - present): part 2 - patent published
{{output}}
Introduction: The emergence of drug resistance poses a serious threat to cancer chemotherapy. by a single agent. Tumor cell heterogeneity, mutation and/or desensitization of receptor render monotherapy ineffective. Combination en... ...
